BOT.AX stock falls 42.61% to A$0.066 on ASX 17 Feb 2026: watch March earnings

BOT.AX stock plunged 42.61% to A$0.066 on the ASX on 17 Feb 2026, trading 90,907,784 shares as investors reacted ahead of a scheduled earnings announcement. The fall leaves Botanix Pharmaceuticals Limited (BOT.AX) well below its 50-day average of A$0.12195 and 200-day average of A$0.17871, reflecting heavy selling pressure in the biotech sector. With an upcoming earnings date on 4 Mar 2026, traders are pricing higher execution and clinical risks. We break down drivers, valuation, technicals and Meyka AI forecasts to frame risk and opportunity for short-term active traders.

BOT.AX stock intraday move and volume

The intraday move was decisive: price fell from an open of A$0.07 to a day low of A$0.066, with a close at A$0.066 and a one-day change of -0.049 or -42.61%. Volume surged to 90,907,784 versus an average volume of 4,859,633, marking BOT.AX as one of the most active ASX names by share turnover today.

High volume with a large one-day percentage decline signals distribution. For active traders, the volume spike increases liquidity but also confirms broad selling interest rather than a thin-market move.

Why the sell-off: earnings timing and clinical risk

Botanix faces an earnings announcement on 4 Mar 2026 and the market is likely repricing clinical, regulatory and funding risk ahead of that date. BOT.AX’s pipeline includes Sofpironium Bromide, BTX 1503, BTX 1702, BTX 1801 and BTX 1204A; absent fresh positive data or clear funding plans, sentiment can swing quickly in biotechnology.

Investors should note shares outstanding of 1,970,102,820 and past capital raises in the sector; potential dilution and cash runway questions often drive sharp pre-earnings moves in small-cap biotech stocks.

BOT.AX stock valuation and financials

On fundamentals, Botanix shows a market cap of A$220,651,516, trailing EPS of -0.05 and a negative PE of -2.24, reflecting losses. Key valuation ratios include price-to-sales 38.11 and price-to-book 2.58, which imply a premium to revenue despite limited near-term sales.

Liquidity metrics are mixed: current ratio 3.99 indicates short-term coverage, while operating cash flow per share is -0.04196. Debt-to-equity is 0.40, not excessive, but free cash flow trends and R&D expense cuts will define near-term funding needs.

Technical indicators and trading outlook for BOT.AX stock

Technically, BOT.AX sits below both the 50-day (A$0.12195) and 200-day (A$0.17871) averages, a bearish regime for trend-followers. RSI reads 43.70, ADX 19.23 (no clear trend), and Bollinger middle band is A$0.12, showing the price is trading near the lower band.

For most active traders, key levels are A$0.075 (intraday resistance), A$0.066 (support today) and A$0.12 (short-term MA). Momentum indicators suggest consolidation risk; stops on the downside and tight position sizing are critical given intraday volatility.

Meyka AI grade and model forecast for BOT.AX stock

Meyka AI rates BOT.AX with a score out of 100: 64.76 | Grade: B | Suggestion: HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. The grade is informational and not investment advice.

Meyka AI’s forecast model projects monthly A$0.12 and quarterly A$0.08. Compared with the current price A$0.066, the monthly projection implies an 81.82% upside and the quarterly projection implies a 21.21% upside. Forecasts are model-based projections and not guarantees.

Analyst ratings, price targets and market context

Third-party screening shows a company rating of D+ (Strong Sell) dated 13 Feb 2026, indicating divergent views across providers. There is no consensus price target published publicly today, increasing uncertainty for retail traders.

Reasonable scenario-based price targets for active portfolios: a conservative target A$0.08 (implied upside 21.21%) and an optimistic target A$0.18 (implied upside 172.73%). Use scenario plans and cash management, because biotech sector moves can be binary around clinical or regulatory outcomes.

Final Thoughts

BOT.AX stock recorded a sharp sell-off on 17 Feb 2026, dropping to A$0.066 on heavy volume of 90,907,784 shares as traders positioned ahead of a 4 Mar 2026 earnings announcement. Fundamentals show a market cap of A$220,651,516, EPS -0.05, price-to-sales 38.11, and a current ratio near 4.00, which gives some short-term liquidity cushion but not a protection from continued sentiment-driven declines. Technically the share price sits under the 50- and 200-day averages, with RSI 43.70 and ADX 19.23, indicating no established uptrend. Meyka AI rates BOT.AX at 64.76 (B) — HOLD and projects monthly A$0.12 and quarterly A$0.08, implying 81.82% and 21.21% upside respectively from current levels. These model outputs are projections, not guarantees. Active traders should plan position size and stop loss, watch the March earnings bulletin closely, and monitor company statements and liquidity moves. For further real-time updates see our Botanix page on Meyka and the trading note on recent market comparisons source and Meyka BOT.AX page.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.